MetaCap

Bolt Biotherapeutics (BOLT) vs Citius Pharmaceuticals (CTXR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $12.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLT+36.39%CTXR+1.48%
+89%+29%-31%
Oct 7, 20261 yearNov 20, 2026
BOLT+19.46%CTXR+1.82%
+64%+21%-23%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLT versus CTXR key metrics
MetricBOLTCTXR
Share price$4.91$0.5085
Market cap$12.80M$13.96M
1-day change-2.96%+2.27%
YTD return—-34.56%
1-year return—-55.39%
5-year return—-98.79%
EPS (TTM)$-14.00$-1.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.70M—
Revenue growth (YoY)+0.07%—
Net income (latest FY)$-33.38M$-39.74M
Operating margin-469.30%—
Net margin-433.74%—
52-week high$7.78$1.54
52-week low$3.10$0.37
Distance from 52-week high-36.89%-66.98%
Analyst consensusnonenone
Avg. price target upside+490.63%+686.63%
Average volume257.43K275.44K
Shares outstanding2.61M27.45M
Employees2323
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bolt Biotherapeutics

BOLT stock →

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

BOLT vs CTXR FAQ

Which is bigger, Bolt Biotherapeutics or Citius Pharmaceuticals?

Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $12.80M for Bolt Biotherapeutics (BOLT).

Are Bolt Biotherapeutics and Citius Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons